---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-086088"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:12:19.874261+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Protagonist Q2 net loss $30.6M; cash $595.4M; JNJ-2113 Phase 3 data expected Q4 2024

## Summary
- Q2 net loss of $30.6M ($0.50/share) vs $38.5M loss in Q2 2023; six-month net income $176.7M from Takeda upfront.
- Cash, equivalents and marketable securities of $595.4M as of June 30, 2024; runway through end of 2027.
- JNJ-2113 Phase 3 ICONIC-LEAD and ICONIC-TOTAL in psoriasis primary endpoint completion expected Q4 2024.
- Phase 2b ANTHEM in ulcerative colitis primary endpoint completion also expected Q4 2024; Phase 3 VERIFY rusfertide topline due Q1 2025.
- Dr. Newman Yeilding appointed Chief Scientific Advisor effective August 1, 2024.

## SEC filing metadata
- accession: 0001104659-24-086088
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465924086088/0001104659-24-086088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465924086088/tm2419327d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-086088
- JSON: https://secwatch.observer/filing/0001104659-24-086088.json
- Plain text: https://secwatch.observer/filing/0001104659-24-086088.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.